Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma

  1. H. Alejandro Preti, MD;
  2. Fernando Cabanillas, MD;
  3. Moshe Talpaz, MD;
  4. Susan L. Tucker, PhD;
  5. John F. Seymour, MB, BS; and
  6. Razelle Kurzrock, MD
  1. From The University of Texas M.D. Anderson Cancer Center, Houston, Texas; and Royal Melbourne Hospital, Melbourne, Australia. Requests for Reprints: Razelle Kurzrock, MD, Department of Bioimmunotherapy, Box 302, The M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Current Author Addresses: Dr. Preti: San Martin de Tours 2980, 1425 Capital Federal, Buenos Aires, Argentina.

    Abstract

    Background: Interleukin-6 has important lymphoid bioregulatory effects, and serum levels of interleukin-6 are often elevated in patients with lymphoma.

    Objective: To determine the relation between serum levels of interleukin-6 before treatment and outcome in patients with diffuse large-cell lymphoma.

    Design: Retrospective cohort analysis with multivariate analysis.

    Setting: Tertiary referral center.

    Participants: 118 untreated patients with diffuse large-cell lymphoma who were enrolled in frontline chemotherapy protocols and 45 healthy controls.

    Measurements: Serum levels of interleukin-6 were measured by using a sensitive enzyme-linked immunosorbent assay. Levels below the upper limit of the range for controls were considered normal. Outcomes were complete response, failure-free survival, and overall survival.

    Results: Serum levels of interleukin-6 were higher in patients with lymphoma (median, 4.6 pg/mL [range, undetectable to 224 pg/mL]) than in controls (median, undetectable [range, undetectable to 4.3 pg/mL]) (P = 0.009). The complete response rate was 95% for persons with normal interleukin-6 levels and 66% for persons with high interleukin-6 levels (P = 0.001). Patients with high interleukin-6 levels had inferior failure-free and overall survival rates (P < 0.001 for both comparisons). The actuarial 4-year failure-free and overall survival rates were 72% and 85%, respectively, for persons with normal interleukin-6 levels and 37% and 46%, respectively, for persons with high interleukin-6 levels. In multivariate analysis, interleukin-6 was selected as the most significant predictor of complete response and failure-free survival. Failure-free and overall survival of patients stratified according to International Prognostic Index score could be further stratified by interleukin-6 level (P ≤ 0.03 for all comparisons).

    Conclusion: In patients with diffuse large-cell lymphoma, serum interleukin-6 levels are an independent prognostic factor for complete response and failure-free survival.

    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med August 1, 1997 vol. 127 no. 3 186-194
    1. » Abstract
    2. Figures
    3. Full Text
    4. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues